10x Genomics Statistics

Total Valuation

10x Genomics has a market cap or net worth of MXN 50.66 billion. The enterprise value is 43.11 billion.

Market Cap	50.66B
Enterprise Value	43.11B

Important Dates

The last earnings date was Thursday, February 12, 2026.

Earnings Date	Feb 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	117.67M
Shares Outstanding	n/a
Shares Change (YoY)	+3.57%
Shares Change (QoQ)	+1.26%
Owned by Insiders (%)	8.09%
Owned by Institutions (%)	93.75%
Float	115.48M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.38
PB Ratio	3.53
P/TBV Ratio	3.86
P/FCF Ratio	21.63
P/OCF Ratio	20.68
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-54.99
EV / Sales	3.90
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	18.40

Financial Position

The company has a current ratio of 4.46, with a Debt / Equity ratio of 0.11.

Current Ratio	4.46
Quick Ratio	3.95
Debt / Equity	0.11
Debt / EBITDA	n/a
Debt / FCF	0.65
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -5.78% and return on invested capital (ROIC) is -7.49%.

Return on Equity (ROE)	-5.78%
Return on Assets (ROA)	-6.40%
Return on Invested Capital (ROIC)	-7.49%
Return on Capital Employed (ROCE)	-11.29%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	9.82M
Profits Per Employee	-665,477
Employee Count	1,178
Asset Turnover	0.66
Inventory Turnover	2.85

Taxes

In the past 12 months, 10x Genomics has paid 65.48 million in taxes.

Income Tax	65.48M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -24.55% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-24.55%
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	28.10
Average Volume (20 Days)	919

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.40

Income Statement

In the last 12 months, 10x Genomics had revenue of MXN 11.57 billion and -783.93 million in losses. Loss per share was -6.28.

Revenue	11.57B
Gross Profit	8.00B
Operating Income	-1.81B
Pretax Income	-718.45M
Net Income	-783.93M
EBITDA	-1.15B
EBIT	-1.81B
Loss Per Share	-6.28

Full Income Statement

Balance Sheet

The company has 9.42 billion in cash and 1.52 billion in debt, giving a net cash position of 7.90 billion.

Cash & Cash Equivalents	9.42B
Total Debt	1.52B
Net Cash	7.90B
Net Cash Per Share	n/a
Equity (Book Value)	14.34B
Book Value Per Share	112.27
Working Capital	9.56B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.45 billion and capital expenditures -106.85 million, giving a free cash flow of 2.34 billion.

Operating Cash Flow	2.45B
Capital Expenditures	-106.85M
Free Cash Flow	2.34B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 69.13%, with operating and profit margins of -15.60% and -6.77%.

Gross Margin	69.13%
Operating Margin	-15.60%
Pretax Margin	-6.21%
Profit Margin	-6.77%
EBITDA Margin	-9.97%
EBIT Margin	-15.60%
FCF Margin	20.24%

Dividends & Yields

10x Genomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.57%
Shareholder Yield	-3.57%
Earnings Yield	-1.55%
FCF Yield	4.62%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

10x Genomics has an Altman Z-Score of 2.67 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.67
Piotroski F-Score	4